Harnessing Gene Expression Profiling In Search Of New Candidate Genes For Ara-C Resistance In Acute Myeloid Leukemia

Wide inter-individual variation in terms of treatment outcome and toxic side effects of treatment exist among patients with AML receiving chemotherapy with cytarabine (Ara-C) and daunorubicin. We have previously evaluated the expression of the major genes involved in cytarabine transport and metabol...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2013-11, Vol.122 (21), p.1299-1299
Main Authors: Abraham, Ajay, Varatharajan, Savitha, Karathedath, Sreeja, Velayudhan, Shaji R, Srivastava, Alok, Mathews, Vikram, Balasubramanian, Poonkuzhali
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Wide inter-individual variation in terms of treatment outcome and toxic side effects of treatment exist among patients with AML receiving chemotherapy with cytarabine (Ara-C) and daunorubicin. We have previously evaluated the expression of the major genes involved in cytarabine transport and metabolism on ex-vivo Ara-C response and compared it with cytogenetic and molecular markers in AML (Blood (ASH Annual Meeting Abstracts) 2011 118: Abstract 3481). Our candidate gene expression data led us to propose Ara-C resistance index (Ara-C RI) (RI = ΔCT (DCK X ENT1)/ ΔCT CDA), which incorporates candidate Ara-C metabolizing genes whose RNA expression are significantly associated with ex-vivo Ara-C cytotoxicity. Ara-C RI values were significantly higher in resistant (IC50 >80 uM) and intermediate (IC50 6.25-80uM) samples when compared to sensitive samples (IC50
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V122.21.1299.1299